Document is current
Any future updates will be listed below
-
Authors
McCracken, Celeste https://orcid.org/0000-0003-1285-2393
Raisi-Estabragh, Zahra https://orcid.org/0000-0002-7757-5465
Veldsman, Michele https://orcid.org/0000-0003-2192-378X
Raman, Betty
Dennis, Andrea
Husain, Masud https://orcid.org/0000-0002-6850-9255
Nichols, Thomas E. https://orcid.org/0000-0002-4516-5103
Petersen, Steffen E. https://orcid.org/0000-0003-4622-5160
Neubauer, Stefan
-
Funding
Funding for this research was provided by:
British Heart Foundation (FS/17/81/33318)
DH | National Institute for Health Research (IS-BRC-1215-20008)
- License Information
-
More Information
Article History
Received: 13 December 2021
Accepted: 28 November 2022
First Online: 21 December 2022
Competing interests
: SEP provides consultancy and owns stock in to Cardiovascular Imaging Inc, Calgary, Alberta, Canada. BR consulted for Axcella Therapeutics. AD is an employee and shareholder in Perspectum Ltd, Oxford, UK. SN is a founder, shareholder and former board member of Perspectum. All other authors declare no other competing interests.
